Prognosis

Moderna Poised to Take Vaccine Spotlight With Data Due

Initial verdict could come in days as national cases ramp up
Effectiveness expected to be similar to Pfizer’s 90% rate

WATCH: Moderna Inc. says it has accumulated enough volunteers to allow a preliminary analysis of its Covid-19 vaccine shot. Daybreak: Asia.” (Source: Bloomberg)

Have a confidential tip for our reporters? Get in Touch

Before it’s here, it’s on the Bloomberg Terminal

LEARN MORE

By Robert Langreth

November 11, 2020 at 3:37 PM EST

Updated on

November 12, 2020 at 5:41 AM EST

This article is for subscribers only.

Now it’s Moderna Inc.’s time to be in the spotlight.

The same U.S. explosion of Covid-19 cases that helped Pfizer Inc. get results for its vaccine trial earlier this week is helping speed along Moderna’s trial. Moderna said Wednesday its study has accumulated more than 53 infections, allowing a preliminary analysis of the shot’s effectiveness to begin. The shares jumped.

Have a confidential tip for our reporters? Get in Touch

Before it’s here, it’s on the Bloomberg Terminal

LEARN MORE